The PhaSeal® System Helps Comply with New Legislation
Using PhaSeal Contributes to a Reduced Exposure Potential for Healthcare Workers
Columbus, OH, May 19, 2011 --(PR.com)-- Carmel Pharma can help hospitals comply with new legislation passed last month in Washington. Senate Bill 5594 requires hospitals to protect healthcare workers who handle chemotherapy and other hazardous drugs in the workplace. Washington is the first state in the U.S. to require protection for healthcare workers by directing the Department of Labor & Industries to adopt safe handling requirements of hazardous drugs.
PhaSeal is an ideal solution as it is the only clinically proven closed-system drug transfer device designed to prevent hazardous drug exposure from preparation and administration to waste disposal. The unique airtight Expansion Chamber and dry, leakproof connections make it the only device that meets the National Institute for Occupational Safety and Health (NIOSH) and International Society of Oncology Pharmacy Practitioners (ISOPP) definitions of a CSTD. PhaSeal is also validated by 17 independent, peer-reviewed, published clinical studies.
In the 2004 NIOSH Alert, it states that “working with or near hazardous drugs in healthcare settings may cause skin rashes, infertility, miscarriage, birth defects and possibly leukemia or other cancers.”1 “Medical personnel handling hazardous drugs are being exposed to very dangerous chemicals that are helpful for sick patients who need them, but harmful – possibly even deadly – to healthy people who don’t,” says Dave Schneider, president of Carmel Pharma, Inc. “As a trusted leader in the ‘safe handling’ industry, we take great responsibility in providing a leakproof and airtight closed-system drug transfer device so healthcare institutions can protect their workers and maintain compliance with safety standards.”
The Joint Commission (TJC), Occupational Safety & Health Administration (OSHA) and NIOSH recently teamed up to impart the same message in a letter that highlights the need for safe practices in U.S. hospitals. “This is the first time I have seen TJC pair up with NIOSH and OSHA to stress the importance of safely handling hazardous drugs. Their partnership sends a powerful message and I think we will see more of this kind of thing,” says Schneider.
About Carmel Pharma (the maker of the PhaSeal System)
Carmel Pharma AB, headquartered in Gothenburg, Sweden, is the manufacturer of the PhaSeal System for the safe handling of hazardous drugs. In the United States, PhaSeal is distributed by a U.S. affiliate office, Carmel Pharma, Inc., located in Columbus, OH. The PhaSeal System has been in use in the U.S. since 1999 and implemented in more than 2000 cancer facilities, infusion centers and private practices, including M.D. Anderson and Texas Children’s in Houston, TX; City of Hope in Duarte, CA; Dana Farber Cancer Institute in Boston, MA; Vanderbilt University Medical Center in Nashville, TN; and Johns Hopkins University in Baltimore, MD, just to name a few. For more information on Carmel Pharma or the PhaSeal System, please visit www.phaseal.com or email info@carmelpharmausa.com. To request additional product details, high-resolution imagery, story ideas and expert references, or to learn more about the topic of safe handling from today’s clinical thought leaders, please visit www.carmelpharmausa.com/media or contact Laura Scherer at 614-318-2635 or laura.scherer@carmelpharma.com.
###
[1] National Institute for Occupational Safety and Health. The NIOSH Publication No. 2004-165 page. Available at: www.cdc.gov/niosh/docs/2004-165/. Accessed May 5, 2011.
PhaSeal is an ideal solution as it is the only clinically proven closed-system drug transfer device designed to prevent hazardous drug exposure from preparation and administration to waste disposal. The unique airtight Expansion Chamber and dry, leakproof connections make it the only device that meets the National Institute for Occupational Safety and Health (NIOSH) and International Society of Oncology Pharmacy Practitioners (ISOPP) definitions of a CSTD. PhaSeal is also validated by 17 independent, peer-reviewed, published clinical studies.
In the 2004 NIOSH Alert, it states that “working with or near hazardous drugs in healthcare settings may cause skin rashes, infertility, miscarriage, birth defects and possibly leukemia or other cancers.”1 “Medical personnel handling hazardous drugs are being exposed to very dangerous chemicals that are helpful for sick patients who need them, but harmful – possibly even deadly – to healthy people who don’t,” says Dave Schneider, president of Carmel Pharma, Inc. “As a trusted leader in the ‘safe handling’ industry, we take great responsibility in providing a leakproof and airtight closed-system drug transfer device so healthcare institutions can protect their workers and maintain compliance with safety standards.”
The Joint Commission (TJC), Occupational Safety & Health Administration (OSHA) and NIOSH recently teamed up to impart the same message in a letter that highlights the need for safe practices in U.S. hospitals. “This is the first time I have seen TJC pair up with NIOSH and OSHA to stress the importance of safely handling hazardous drugs. Their partnership sends a powerful message and I think we will see more of this kind of thing,” says Schneider.
About Carmel Pharma (the maker of the PhaSeal System)
Carmel Pharma AB, headquartered in Gothenburg, Sweden, is the manufacturer of the PhaSeal System for the safe handling of hazardous drugs. In the United States, PhaSeal is distributed by a U.S. affiliate office, Carmel Pharma, Inc., located in Columbus, OH. The PhaSeal System has been in use in the U.S. since 1999 and implemented in more than 2000 cancer facilities, infusion centers and private practices, including M.D. Anderson and Texas Children’s in Houston, TX; City of Hope in Duarte, CA; Dana Farber Cancer Institute in Boston, MA; Vanderbilt University Medical Center in Nashville, TN; and Johns Hopkins University in Baltimore, MD, just to name a few. For more information on Carmel Pharma or the PhaSeal System, please visit www.phaseal.com or email info@carmelpharmausa.com. To request additional product details, high-resolution imagery, story ideas and expert references, or to learn more about the topic of safe handling from today’s clinical thought leaders, please visit www.carmelpharmausa.com/media or contact Laura Scherer at 614-318-2635 or laura.scherer@carmelpharma.com.
###
[1] National Institute for Occupational Safety and Health. The NIOSH Publication No. 2004-165 page. Available at: www.cdc.gov/niosh/docs/2004-165/. Accessed May 5, 2011.
Contact
Carmel Pharma, Inc.
Laura Scherer
614-318-2622
www.carmelpharma.com
Laura Scherer
614-318-2622
www.carmelpharma.com
Contact
Categories